REG - OptiBiotix Health - Grant of Options <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

06/07/2017 07:05

RNS Number : 2597K
OptiBiotix Health PLC
06 July 2017
OptiBiotix Health plc
("OptiBiotix"orthe Company")
Grant of Options
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the grant of options to Per Rehn and Christina Wood, both Directors of the Company at an exercise price of 69.5p. Full details of the options agreement for the relevant parties are set out in the table below.

Per Rehn
Number of Shares under option
500,000
Exercise Price
69.5p
Expiration date
23 June 2027
Interests following grant (shares/options)
500,000 options
Christina Wood
Number of Shares under option
500,000
Exercise Price
69.5p
Expiration date
23 June 2027
Interests following grant (shares/options)
500,000 options
Under the terms of the agreement the options are exercisable on meeting commercial targets including cumulative revenues for each area of director's responsibility. 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
Per Rehn
2
Reason for notification
a.
Position/Status
PDMR
b.
Initial notification/
Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
OptiBiotix Health Plc
b.
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

Identification Code
Options over 500,000 ordinary shares of 2p each


ISIN: GB00BP0RTP38 

b.
Nature of the transaction
Award of option to purchase ordinary shares of the Company. Following the transaction, Mr Per Rehn has an interest in options 500,000 over ordinary shares.
c.
Price(s) and volume(s)


Price(s)
Volume(s)

69.5p
500,000
d.
Aggregated information
- Aggregated Volume
- Price
500,000
69.5p
e.
Date of the transaction
29 June 2017
f.
Place of the transaction
London Stock Exchange, AIM
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
Christina Wood
2
Reason for notification
a.
Position/Status
PDMR
b.
Initial notification/
Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
OptiBiotix Health Plc
b.
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

Identification Code
Options over 500,000 ordinary shares of 2p each


ISIN: GB00BP0RTP38

b.
Nature of the transaction
Award of option to purchase ordinary shares of the Company. Following the transaction, Mrs Christina Wood has an interest in options 500,000 over ordinary shares.
c.
Price(s) and volume(s)






Price(s)
Volume(s)

69.5p
500,000

d.
Aggregated information
- Aggregated Volume
- Price
500,000
69.5p
e.
Date of the transaction
29 June 2017
f.
Place of the transaction
London Stock Exchange, AIM
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the grant of options to Commercial Director Per Rehne, and Sales and Marketing Director Christina Wood, who are leading the commercialisation of OptiBiotix's products in global markets. Christina is leading the commercialisation of SlimBiome whilst Per is leading the commercialisation of LPLDL..The options are exercisable on achieving a number of cumulative revenue milestones for each area of director's responsibility designed to focus both efforts and activity on rapidly growing revenues."
For further information, please contact:
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below


Cairn Financial Advisers LLP (NOMAD)
Tel: 020 7213 0880
Liam Murray / Jo Turner

finnCap (Broker)
Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)

Tony Quirke (Corporate Broking)



Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHSSWEFIFWSELW